IRLAB: Invitation to the interim report for Q3 2025 presentation and webcast

Gothenburg, Sweden, October 23, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January – September 2025. The interim report will be published on Wednesday, October 29 at 07:00 CEST.

IRLAB appoints Gustaf Albèrt as the new Chief Financial Officer.

IRLAB to present at Redeye Theme: Neurology